Efficacy and Safety of Testosterone in the Management of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Journal of Sexual Medicine

Volumn 9, Issue 4, 2012, Pages 1134-1148

  Davis, Susan R ^a   Braunstein, Glenn D ^b  

^a MONASH UNIVERSITY   (Australia)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cardiovascular; Hypoactive sexual desire disorder; Postmenopausal women; Sexual dysfunction treatment; Testosterone therapy; Transdermal testosterone

Indexed keywords

ANDROGEN RECEPTOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LUTEINIZING HORMONE; PLACEBO; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ACNE; ALOPECIA; ANDROGEN DEFICIENCY; ARTICLE; BREAST CANCER; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CLITEROMEGALY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; GEL; GYNECOLOGIC DISEASE; HAIR GROWTH; HIGH RISK POPULATION; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; LIVER TOXICITY; LUTEAL PHASE; MEDICAL LITERATURE; MEDICAL SOCIETY; MENSTRUAL CYCLE; PEER REVIEW; POLYCYTHEMIA; POSTMENOPAUSE; PRIORITY JOURNAL; SEXUAL FUNCTION; SEXUAL HEALTH; SIDE EFFECT; SLEEP APNEA SYNDROME; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

EID: 84859266256     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02634.x     Document Type: Article

References (98)

1. Bachmann G. Female sexuality and sexual dysfunction: Are we stuck on the learning curve? J Sex Med 2006;3:639-45.
2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-44.
3. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:762-74.
4. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med 2008;168:1441-9.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Revised 4th edition. Washington, DC: American Psychiatric Association; 2000.
6. Testosterone patch: New drug. Don't use to stimulate women's sexual desire. Prescrire Int 2007;16:190-2.
7. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause 2006;13:46-56.
8. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: Prevalence and correlates. Obstet Gynecol 2008;112:970-8.
9. Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: A survey of Western European women. J Sex Med 2006;3:212-22.
10. Davison SL, Bell RJ, LaChina M, Holden SL, Davis SR. The relationship between self-reported sexual satisfaction and general well-being in women. J Sex Med 2009;6:2690-7.
11. Urquhart DM, Bell R, Cicuttini FM, Cui J, Forbes A, Davis SR. Low back pain and disability in community-based women: Prevalence and associated factors. Menopause 2009;16:24-9.
12. Botlero R, Bell RJ, Urquhart DM, Davis SR. Urinary incontinence is associated with lower psychological general well-being in community-dwelling women. Menopause 2010;17:332-7.
13. Braunstein GD. The Endocrine Society Clinical Practice Guideline and The North American Menopause Society position statement on androgen therapy in women: Another one of Yogi's forks. J Clin Endocrinol Metab 2007;92:4091-3.
14. Moynihan R. The marketing of a disease: Female sexual dysfunction. BMJ 2005;330:192-4.
15. Wierman ME, Nappi RE, Avis N, Davis SR, Labrie F, Rosner W, Shifren JL. Endocrine aspects of women's sexual function. J Sex Med 2010;7(1 Pt 2):561-85.
16. Braunstein GD, Reitz RE, Buch A, Schnell D, Caulfield MP. Testosterone reference ranges in normally cycling healthy premenopausal women. J Sex Med 2011;8:2924-34.
17. Lobo RA. Androgens in postmenopausal women: Production, possible role, and replacement options. Obstet Gynecol Surv 2001;56:361-76.
18. Mushayandebvu T, Castracane VD, Gimpel T, Adel T, Santoro N. Evidence for diminished midcycle ovarian androgen production in older reproductive aged women. Fertil Steril 1996;65:721-3.
19. Longcope C. Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab 1986;15:213-28.
20. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981;53:58-68.
21. Akin F, Bastemir M, Alkis E, Kaptanoglu B. SHBG levels correlate with insulin resistance in postmenopausal women. Eur J Intern Med 2009;20:162-7.
22. Loukovaara M, Carson M, Adlercreutz H. Regulation of production and secretion of sex hormone-binding globulin in HepG2 cell cultures by hormones and growth factors. J Clin Endocrinol Metab 1995;80:160-4.
23. Edmunds SE, Stubbs AP, Santos AA, Wilkinson ML. Estrogen and androgen regulation of sex hormone binding globulin secretion by a human liver cell line. J Steroid Biochem Mol Biol 1990;37:733-9.
24. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85:2832-8.
25. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: Changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847-53.
26. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: The Rancho Bernardo Study. J Clin Endocrinol Metab 2000;85:645-51.
27. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91-6.
28. Bell RJ, Donath S, Davison SL, Davis SR. Endogenous androgen levels and well-being: Differences between premenopausal and postmenopausal women. Menopause 2006;13:65-71.
29. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003;49:1381-95.
30. Labrie F. Extragonadal synthesis of sex steroids: Intracrinology. Ann Endocrinol (Paris) 2003;64:95-107.
31. Nathorst-Boos J, von Schoultz H. Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol Obstet Invest 1992;34:97-101.
32. Hulter B, Lundberg PO. Sexual function in women with hypothalamo-pituitary disorders. Arch Sex Behav 1994;23:171-83.
33. Sheaffer AT, Lange E, Bondy CA. Sexual function in women with Turner syndrome. J Womens Health (Larchmt) 2008;17:27-33.
34. Guay A, Jacobson J, Munarriz R, Traish A, Talakoub L, Quirk F, Goldstein I, Spark R. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part B: Reduced serum androgen levels in healthy premenopausal women with complaints of sexual dysfunction. Int J Impot Res 2004;16:121-9.
35. Tuiten A, Van Honk J, Koppeschaar H, Bernaards C, Thijssen J, Verbaten R. Time course of effects of testosterone administration on sexual arousal in women. Arch Gen Psychiatry 2000;57:149-53, discussion 155-146.
36. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA 1983;249:2195-8.
37. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341-52.
38. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153-60.
39. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36.
40. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, Watts NB. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-9.
41. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, Rodenberg CA, Wekselman K, Casson P. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol 2005;105:944-52.
42. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, Moufarege A, Rodenberg C, Buch A, Purdie DW. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Menopause 2006;13:387-96.
43. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Caramelli KE, Mazer NA. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8.
44. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: Results from the INTIMATE NM1 Study. Menopause 2006;13:770-9.
45. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J, Davis S. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-33.
46. Procter & Gamble Pharmaceuticals I. Intrinsa NDA No. 21-769. Advisory committee briefing document. 2004. Available at: (accessed May 14, 2011).
47. Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause 2007;14:985-94.
48. Davis SR, Goldstat R, Papalia MA, Shah S, Kulkarni J, Donath S, Bell RJ. Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: A randomized, placebo-controlled trial. Menopause 2006;13:37-45.
49. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, Hirschberg AL, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359:2005-17.
50. Kingsberg S, Shifren J, Wekselman K, Rodenberg C, Koochaki P, Derogatis L. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2007;4:1001-8.
51. Food and Drug Administration. Intrinsa (testosterone transdermal system): NDA 21-769. Review by the Division of Reproductive and Urologic Drug Products. 2004. Available at: (accessed May 14, 2011).
52. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: A systematic review and meta-analysis. Eur Urol 2005;48:5-26.
53. Brown WA. Placebo as a treatment for depression. Neuropsychopharmacology 1994;10:265-9, discussion 271-288.
54. Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: A randomized double-blind and placebo-controlled study. J Diabetes Complications 2004;18:205-10.
55. Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ. Sildenafil for male erectile dysfunction: A systematic review and meta-analysis. Arch Intern Med 2002;162:1349-60.
56. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-6.
57. Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration: Safety issues and controversies. J Sex Med 2007;4:859-66.
58. Braunstein GD. Safety of testosterone treatment in postmenopausal women. Fertil Steril 2007;88:1-17.
59. Meyer WJ 3rd, Webb A, Stuart CA, Finkelstein JW, Lawrence B, Walker PA. Physical and hormonal evaluation of transsexual patients: A longitudinal study. Arch Sex Behav 1986;15:121-38.
60. Brand JS, van der Schouw YT. Testosterone, SHBG and cardiovascular health in postmenopausal women. Int J Impot Res 2010;22:91-104.
61. Laughlin GA, Goodell V, Barrett-Connor E. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab 2010;95:740-7.
62. Barrett-Connor E, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ 1995;311:1193-6.
63. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, Nolan J. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999;44:1012-20.
64. Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001;86:158-61.
65. Basaria S, Nguyen T, Rosenson RS, Dobs AS. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. Clin Endocrinol (Oxf) 2002;57:209-14.
66. Buckler HM, McElhone K, Durrington PN, Mackness MI, Ludlam CA, Wu FC. The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) 1998;49:173-8.
67. Schlatterer K, Yassouridis A, von Werder K, Poland D, Kemper J, Stalla GK. A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients. Arch Sex Behav 1998;27:475-92.
68. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997;47:337-42.
69. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, Krogh V, Lenner P, Shore RE, Biessy C, Muti P, Riboli E, Koenig KL, Levitz M, Stattin P, Berrino F, Hallmans G, Kaaks R, Toniolo P, Zeleniuch-Jacquotte A. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004;108:425-32.
70. Zang H, Sahlin L, Masironi B, Eriksson E, Linden Hirschberg A. Effects of testosterone treatment on endometrial proliferation in postmenopausal women. J Clin Endocrinol Metab 2007;92:2169-75.
71. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
72. Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res 2009;11:212.
73. Danforth KN, Eliassen AH, Tworoger SS, Missmer SA, Barbieri RL, Rosner BA, Colditz GA, Hankinson SE. The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women. Int J Cancer 2010;126:199-207.
74. Traish A, Fetten K, Miner M, Hansen ML, Guay A. Testosterone and risk of breast cancer: Appraisal of existing evidence. Horm Mol Biol Clin Invest 2010;2:177-90.
75. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N. Androgen therapy in women: An Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006;91:3697-710.
76. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH. Postmenopausal hormone therapy: An Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:s1-66.
77. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006;166:1483-9.
78. Jick SS, Hagberg KW, Kaye JA, Jick H. Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer. Obstet Gynecol 2009;113:74-80.
79. Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med 2009;169:41-6.
80. Davis SR, Wolfe R, Farrugia H, Ferdinand A, Bell RJ. The incidence of invasive breast cancer among women prescribed testosterone for low libido. J Sex Med 2009;6:1850-6.
81. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004;11:531-5.
82. Somboonporn W, Davis SR. Postmenopausal testosterone therapy and breast cancer risk. Maturitas 2004;49:267-75.
83. Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, Powell D, Bondy C. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003;10:292-8.
84. Hofling M, Hirschberg AL, Skoog L, Tani E, Hagerstrom T, von Schoultz B. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 2007;14:183-90.
85. Burgess HE, Shousha S. An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: A comparison with normal female breast and male breast showing gynaecomastia. J Pathol 1993;170:37-43.
86. Slagter MH, Gooren LJ, Scorilas A, Petraki CD, Diamandis EP. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. J Histochem Cytochem 2006;54:905-10.
87. Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: A double-blind, cross-over study. Psychoneuroendocrinology 1985;10:325-35.
88. Sapienza P, Zingales L, Maestripieri D. Gender differences in financial risk aversion and career choices are affected by testosterone. Proc Natl Acad Sci U S A 2009;106:15268-73.
89. Bos PA, Terburg D, van Honk J. Testosterone decreases trust in socially naive humans. Proc Natl Acad Sci U S A 2010;107:9991-5.
90. Fallon B. "Off-label" drug use in sexual medicine treatment. Int J Impot Res 2008;20:127-34.
91. Snabes M, Milling W, Simes S. Without FDA-approved testosterone to treat women with hypoactive sexual desire disorder US providers rely on off-label prescribing. J Sex Med 2011;8(suppl 2):62, 18A.
92. Snabes MC, Simes SM. Approved hormonal treatments for HSDD: An unmet medical need. J Sex Med 2009;6:1846-9.
93. Shames D, Monroe SE, Davis D, Soule L. Regulatory perspective on clinical trials and end points for female sexual dysfunction, in particular, hypoactive sexual desire disorder: Formulating recommendations in an environment of evolving clinical science. Int J Impot Res 2007;19:30-6.
94. Snabes M, Simes S, Zborowski J, White W. A clear path to approval for LibiGel treatment of women with hypoactive sexual desire disorder. J Sex Med 2008;5:175, 124A.
95. Swanson S, DeRogatis L, Snabes MC, Zborowski J. A newly initiated phase III, randomized, double-blind, placebo-controlled, multicenter study of the safety and efficacy of LibiGel for treatment of HSDD in surgically menopausal women. Annual Meeting of the International Society for the Study of Women's Sexual Health, February 22-25, 2007. Orlando, FL.
96. Snabes M, White W, Connor J, Berry D, Zborowski J, Simes S. A cardiovascular and breast safety study of LibiGel in women with hypoactive sexual desire disorder (HSDD): Study design and description of endpoints. J Sex Med 2008;5:175, 125A.
97. Snabes MC, Berry S, Zborowski J, White W. Low cardiovascular event rate in post-menopausal women with increased cardiovascular risk: Two year blinded summary from the ongoing LibiGel (testosterone gel) safety study. J Sex Med 2011;8(suppl 2):62, 17A.
98. Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol 2011;27:39-48.